Inceptor Bio

Overview

Focused on developing next-generation cell therapies, Inceptor Bio specializes in chimeric antigen receptor (CAR) constructs for challenging cancer types, especially solid tumors. With innovative platforms such as CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) cells, the organization strives to enhance immune cell activation and durability within tumor microenvironments to improve treatment outcomes.

Guided by CEO Matthias Schroff, PhD, the company brings together experts in oncology, gene therapy, and cell therapy to advance research and development. Strategic collaborations with partners like Kineticos Ventures support scientific and business growth. Their therapies are designed for patients with significant unmet medical needs, engaging healthcare providers, research institutions, and pharmaceutical partners in the pursuit of leading-edge solutions in cell therapy.

Basic Information

Contact Details

• Phone: +1 919-521-6400
• Website: inceptor.bio
• LinkedIn: linkedin.com/company/inceptor-bio

Key Focus Areas & Initiatives

• Gene therapy
• Viral vectors
• CART and CAR-NK cell platforms
• Immunology & phagocytes
• CARM technology
• Cell therapy for oncology
• Cancer therapies focused on solid tumors
• Chimeric antigen receptors
• T-cell and macrophage research
• Biotechnology research
• Hospital & health care collaborations

Technologies Used

• Google Cloud Hosting
• Microsoft Office 365
• Mimecast
• Outlook
• Remote